177 related articles for article (PubMed ID: 21862943)
1. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; Hogben K; De Nguyen Q; Coombes RC; Aboagye EO
Nucl Med Commun; 2011 Nov; 32(11):997-1004. PubMed ID: 21862943
[TBL] [Abstract][Full Text] [Related]
2. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer.
Challapalli A; Barwick T; Tomasi G; O' Doherty M; Contractor K; Stewart S; Al-Nahhas A; Behan K; Coombes C; Aboagye EO; Mangar S
Nucl Med Commun; 2014 Jan; 35(1):20-9. PubMed ID: 24201549
[TBL] [Abstract][Full Text] [Related]
3. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
[TBL] [Abstract][Full Text] [Related]
4. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
5. 3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.
Challapalli A; Barwick T; Pearson RA; Merchant S; Mauri F; Howell EC; Sumpter K; Maxwell RJ; Aboagye EO; Sharma R
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):831-40. PubMed ID: 25673055
[TBL] [Abstract][Full Text] [Related]
6.
Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM
Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871
[TBL] [Abstract][Full Text] [Related]
7. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.
Marti-Climent JM; Dominguez-Prado I; Garcia-Velloso MJ; Boni V; Peñuelas I; Toledo I; Richter JA
Rev Esp Med Nucl Imagen Mol; 2014; 33(5):280-5. PubMed ID: 25066253
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
9. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer.
Contractor KB; Kenny LM; Stebbing J; Al-Nahhas A; Palmieri C; Sinnett D; Lewis JS; Hogben K; Osman S; Shousha S; Lowdell C; Coombes RC; Aboagye EO
Clin Cancer Res; 2009 Sep; 15(17):5503-10. PubMed ID: 19706823
[TBL] [Abstract][Full Text] [Related]
10. Comparison of
Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
[TBL] [Abstract][Full Text] [Related]
11. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
[TBL] [Abstract][Full Text] [Related]
12. Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.
Contractor K; Challapalli A; Tomasi G; Rosso L; Wasan H; Stebbing J; Kenny L; Mangar S; Riddle P; Palmieri C; Al-Nahhas A; Sharma R; Turkheimer F; Coombes RC; Aboagye E
Phys Med Biol; 2012 Jun; 57(11):3419-33. PubMed ID: 22572708
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
14. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Kenny L; Coombes RC; Vigushin DM; Al-Nahhas A; Shousha S; Aboagye EO
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1339-47. PubMed ID: 17333178
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
16. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
[TBL] [Abstract][Full Text] [Related]
17. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.
Benz MR; Czernin J; Allen-Auerbach MS; Dry SM; Sutthiruangwong P; Spick C; Radu C; Weber WA; Tap WD; Eilber FC
Cancer; 2012 Jun; 118(12):3135-44. PubMed ID: 22020872
[TBL] [Abstract][Full Text] [Related]
18. Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells.
Li M; Peng Z; Liu Q; Sun J; Yao S; Liu Q
Oncol Rep; 2013 Jan; 29(1):205-11. PubMed ID: 23124523
[TBL] [Abstract][Full Text] [Related]
19. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods.
Kenny LM; Vigushin DM; Al-Nahhas A; Osman S; Luthra SK; Shousha S; Coombes RC; Aboagye EO
Cancer Res; 2005 Nov; 65(21):10104-12. PubMed ID: 16267037
[TBL] [Abstract][Full Text] [Related]
20. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
